Association between the soluble receptor for advanced glycation end products and diabetes mellitus: systematic review and meta-analysis.
Soluble receptor for advanced glycation end products
Type 1 diabetes
Type 2 diabetes
sRAGE
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
26
07
2024
accepted:
16
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
In both type 1 diabetes (T1DM) and type 2 diabetes (T2DM), previous studies have yielded inconsistent findings regarding whether the levels of the soluble receptor for advanced glycation end products (sRAGE) are significantly altered. This meta-analysis aims to systematically evaluate the changes of sRAGE levels in patients with T1DM and T2DM. PubMed, Embase, and Web of Science were systematically searched from inception until April 2024. We included studies reporting sRAGE levels in individuals with T1DM or T2DM, using non-diabetic healthy individuals as the control group. A random-effects model was applied to conduct a meta-analysis of effect measures (means and SDs). 49 datasets from 32 studies, involving 4948 subjects, met the inclusion criteria. A random-effects model meta-analysis showed that sRAGE levels in T1DM subjects (SMD 0.45, CI: 0.16-0.73, P = 0.002) and T2DM subjects with complications (SMD 1.59, CI: 0.77-2.41, P = 0.0001) were significantly higher than those in the control groups. No statistically significant change in sRAGE levels was observed in T2DM subjects without complications (SMD 0.01, CI: -0.61-0.64, P = 0.97). A decrease in sRAGE levels was observed in subjects with newly diagnosed T2DM (SMD-0.40, CI: -0.71- -0.09, P = 0.01). This meta-analysis indicated that sRAGE levels increased in T1DM patients and T2DM patients with complications, while they decreased in newly diagnosed T2DM patients. No significant difference was observed in T2DM patients without complications. Clearly, changes in sRAGE levels in patients with T1DM or T2DM are not uniform, but depend on the different types and stages of the disease. CRD42024521252.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
In both type 1 diabetes (T1DM) and type 2 diabetes (T2DM), previous studies have yielded inconsistent findings regarding whether the levels of the soluble receptor for advanced glycation end products (sRAGE) are significantly altered. This meta-analysis aims to systematically evaluate the changes of sRAGE levels in patients with T1DM and T2DM.
METHODS
METHODS
PubMed, Embase, and Web of Science were systematically searched from inception until April 2024. We included studies reporting sRAGE levels in individuals with T1DM or T2DM, using non-diabetic healthy individuals as the control group. A random-effects model was applied to conduct a meta-analysis of effect measures (means and SDs).
RESULTS
RESULTS
49 datasets from 32 studies, involving 4948 subjects, met the inclusion criteria. A random-effects model meta-analysis showed that sRAGE levels in T1DM subjects (SMD 0.45, CI: 0.16-0.73, P = 0.002) and T2DM subjects with complications (SMD 1.59, CI: 0.77-2.41, P = 0.0001) were significantly higher than those in the control groups. No statistically significant change in sRAGE levels was observed in T2DM subjects without complications (SMD 0.01, CI: -0.61-0.64, P = 0.97). A decrease in sRAGE levels was observed in subjects with newly diagnosed T2DM (SMD-0.40, CI: -0.71- -0.09, P = 0.01).
CONCLUSION
CONCLUSIONS
This meta-analysis indicated that sRAGE levels increased in T1DM patients and T2DM patients with complications, while they decreased in newly diagnosed T2DM patients. No significant difference was observed in T2DM patients without complications. Clearly, changes in sRAGE levels in patients with T1DM or T2DM are not uniform, but depend on the different types and stages of the disease.
PROSPERO REGISTRATION NUMBER
UNASSIGNED
CRD42024521252.
Identifiants
pubmed: 39472884
doi: 10.1186/s12902-024-01759-2
pii: 10.1186/s12902-024-01759-2
doi:
Substances chimiques
Receptor for Advanced Glycation End Products
0
Biomarkers
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
232Subventions
Organisme : National Key Research and Development Program of China
ID : 2018YFC1314100
Organisme : Key-Area Research and Development Program of Guangdong Province
ID : 2019B020230001
Informations de copyright
© 2024. The Author(s).
Références
Atherosclerosis. 2010 Mar;209(1):173-7
pubmed: 19733353
J Pak Med Assoc. 2021 Apr;71(4):1175-1180
pubmed: 34125766
Stat Methods Med Res. 2018 Jun;27(6):1785-1805
pubmed: 27683581
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
Biomolecules. 2022 Apr 04;12(4):
pubmed: 35454131
J Pediatr Endocrinol Metab. 2009 Oct;22(10):895-904
pubmed: 20020577
Diabetes Care. 2014 Jul;37(7):1975-81
pubmed: 24742661
Diabetes Metab Res Rev. 2024 Feb;40(2):e3735
pubmed: 37817474
Cardiovasc Diabetol. 2015 Sep 25;14:126
pubmed: 26408307
J Bone Miner Metab. 2017 Nov;35(6):631-641
pubmed: 27873077
Nutr Metab Cardiovasc Dis. 2015 Feb;25(2):230-5
pubmed: 25467215
Diab Vasc Dis Res. 2008 Sep;5(3):190-7
pubmed: 18777492
Clin Sci (Lond). 2011 Jan;120(2):81-9
pubmed: 20726839
Diabetes Metab Syndr. 2019 Jul - Aug;13(4):2457-2461
pubmed: 31405660
Int J Angiol. 2014 Mar;23(1):11-6
pubmed: 24627612
Expert Opin Investig Drugs. 2012 Jun;21(6):797-805
pubmed: 22519597
J Diabetes Res. 2015;2015:150325
pubmed: 26078977
Curr Diab Rep. 2016 Oct;16(10):100
pubmed: 27612847
Diabetologia. 2006 Nov;49(11):2756-62
pubmed: 16969649
Cardiovasc Diabetol. 2020 Jun 17;19(1):92
pubmed: 32552684
Clin Exp Med. 2007 Dec;7(4):188-90
pubmed: 18188534
Diabet Med. 2013 Jun;30(6):702-9
pubmed: 23432638
Diabetes Metab Res Rev. 2007 Jul;23(5):368-71
pubmed: 17024691
Free Radic Biol Med. 2007 Aug 15;43(4):511-8
pubmed: 17640561
Diabetologia. 2007 Sep;50(9):1819-1825
pubmed: 17639302
Exp Clin Endocrinol Diabetes. 2012 May;120(5):277-81
pubmed: 22549347
Diabetes. 2010 Aug;59(8):2027-32
pubmed: 20522598
Diabetes Metab Syndr. 2022 Mar;16(3):102441
pubmed: 35247657
J Clin Med. 2021 Oct 29;10(21):
pubmed: 34768589
PLoS One. 2015 Sep 01;10(9):e0137330
pubmed: 26325204
Genomics. 1994 Sep 15;23(2):408-19
pubmed: 7835890
Cent Eur J Public Health. 2017 Mar;25(1):3-10
pubmed: 28399348
J Diabetes Complications. 2015 Apr;29(3):422-6
pubmed: 25659638
J Am Soc Nephrol. 2005 Aug;16(8):2363-72
pubmed: 15930093
BMC Endocr Disord. 2013 Aug 21;13:32
pubmed: 23964833
Clin Chem. 2005 Sep;51(9):1749-50
pubmed: 16120960
Vascul Pharmacol. 2012 Nov-Dec;57(5-6):160-7
pubmed: 22750165
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4177-85
pubmed: 26132777
Front Endocrinol (Lausanne). 2021 Aug 26;12:726182
pubmed: 34512554
Med Res Rev. 2020 Jul;40(4):1200-1219
pubmed: 32112452
Arch Med Res. 2011 Oct;42(7):596-601
pubmed: 22100610
J Clin Endocrinol Metab. 2006 Nov;91(11):4628-34
pubmed: 16926247
Diab Vasc Dis Res. 2013 May;10(3):239-45
pubmed: 23091285
Cardiovasc Diabetol. 2022 Jun 6;21(1):95
pubmed: 35668468
J Leukoc Biol. 2013 Jul;94(1):55-68
pubmed: 23543766
J Oral Sci. 2016;58(4):547-553
pubmed: 28025439
Antioxidants (Basel). 2022 Jul 30;11(8):
pubmed: 36009220
Diabetes Care. 2015 Oct;38(10):1891-7
pubmed: 26253728
Open Life Sci. 2020 Jun 11;15(1):364-372
pubmed: 33817224
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120